With the caveat that previous anti-MiHA adoptive immunotherapy clinical studies were done in advanced, hard to treat leukemia patients, it is also possible that the ex vivo generated MiHA-specific T cells used in these trials had reached some level of exhaustion in vitro prior to adoptive transfer. This evidence concerns the gene XIAP and leukemia.